全文获取类型
收费全文 | 101395篇 |
免费 | 7146篇 |
国内免费 | 4483篇 |
专业分类
耳鼻咽喉 | 569篇 |
儿科学 | 1389篇 |
妇产科学 | 1202篇 |
基础医学 | 8260篇 |
口腔科学 | 1646篇 |
临床医学 | 6698篇 |
内科学 | 9998篇 |
皮肤病学 | 2100篇 |
神经病学 | 7812篇 |
特种医学 | 2010篇 |
外国民族医学 | 11篇 |
外科学 | 5680篇 |
综合类 | 15066篇 |
现状与发展 | 6篇 |
预防医学 | 6413篇 |
眼科学 | 1547篇 |
药学 | 27481篇 |
43篇 | |
中国医学 | 11980篇 |
肿瘤学 | 3113篇 |
出版年
2024年 | 284篇 |
2023年 | 1285篇 |
2022年 | 2134篇 |
2021年 | 3132篇 |
2020年 | 2890篇 |
2019年 | 2475篇 |
2018年 | 2630篇 |
2017年 | 3039篇 |
2016年 | 3364篇 |
2015年 | 3388篇 |
2014年 | 6478篇 |
2013年 | 7228篇 |
2012年 | 6579篇 |
2011年 | 7076篇 |
2010年 | 5357篇 |
2009年 | 4856篇 |
2008年 | 4883篇 |
2007年 | 5066篇 |
2006年 | 4524篇 |
2005年 | 4022篇 |
2004年 | 3390篇 |
2003年 | 2960篇 |
2002年 | 2502篇 |
2001年 | 2159篇 |
2000年 | 1843篇 |
1999年 | 1618篇 |
1998年 | 1462篇 |
1997年 | 1348篇 |
1996年 | 1279篇 |
1995年 | 1198篇 |
1994年 | 1065篇 |
1993年 | 874篇 |
1992年 | 857篇 |
1991年 | 809篇 |
1990年 | 796篇 |
1989年 | 727篇 |
1988年 | 675篇 |
1987年 | 589篇 |
1986年 | 593篇 |
1985年 | 886篇 |
1984年 | 837篇 |
1983年 | 615篇 |
1982年 | 626篇 |
1981年 | 561篇 |
1980年 | 503篇 |
1979年 | 374篇 |
1978年 | 287篇 |
1977年 | 221篇 |
1976年 | 194篇 |
1975年 | 138篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
6.
Weina Cheng Yazhi Wang Jingxian Liu Xiaofei Li Ming Yu Cancan Duan Liu Liu Jianyong Zhang 《Journal of applied toxicology : JAT》2022,42(6):970-980
Cantharidin (CTD) is an effective antitumor agent. However, it exhibits significant hepatotoxicity, the mechanism of which remains unclear. In this study, biochemical and histopathological analyses complemented with ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS)-based targeted metabolomic analysis of bile acids (BAs) were employed to investigate CTD-induced hepatotoxicity in rats. Sixteen male and female Sprague–Dawley rats were randomly divided into two groups: control and CTD (1.0 mg/kg) groups. Serum and liver samples were collected after 28 days of intervention. Biochemical, histopathological, and BA metabolomic analyses were performed for all samples. Further, the key biomarkers of CTD-induced hepatotoxicity were identified via multivariate and metabolic pathway analyses. In addition, metabolite–gene–enzyme network and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to identify the signaling pathways related to CTD-induced hepatotoxicity. The results revealed significantly increased levels of biochemical indices (alanine aminotransferase, aspartate aminotransferase, and total bile acid). Histopathological analysis revealed that the hepatocytes were damaged. Further, 20 endogenous BAs were quantitated via UHPLC-MS/MS, and multivariate and metabolic pathway analyses of BAs revealed that hyocholic acid, cholic acid, and chenodeoxycholic acid were the key biomarkers of CTD-induced hepatotoxicity. Meanwhile, primary and secondary BA biosynthesis and taurine and hypotaurine metabolism were found to be associated with the mechanism by which CTD induced hepatotoxicity in rats. This study provides useful insights for research on the mechanism of CTD-induced hepatotoxicity. 相似文献
7.
8.
Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed. 相似文献
9.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):399-407
PurposeTo evaluate the midterm outcomes of percutaneous transluminal renal angioplasty (PTRA) for pediatric renovascular hypertension (RVH).Materials and MethodsThe clinical data of patients who underwent PTRA for RVH in the authors’ hospital from 2012 to 2019 were retrospectively analyzed. Postprocedural blood pressure, glomerular filtration rate (GFR) of the affected kidney, restenosis, and complications were closely monitored.ResultsPTRA was performed in a total of 30 children (20 boys and 10 girls), with a mean age of 7.3 years ± 0.7 (range, 40 days to 13.9 years) and a mean weight of 25.0 kg ± 2.3 (range, 3.4–53 kg). The median follow-up period was 26.5 months (range, 1 month to 7.5 years). Technical success was achieved in 26 (86.7%) of the 30 patients. Restenosis developed in 3 patients (10.0%). Only 1 patient underwent stent implantation, and the stent fractured 8 months later, requiring further intervention. There were no other complications. In terms of clinical benefit of blood pressure control after the initial PTRA procedure, 15 patients (50%) were cured and 7 patients (23.3%) showed improvement. There was no significant difference in the etiology, lesion location, and lesion length between patients with clinical benefit and failure (P = .06, P = .202, and P = .06, respectively). GFR of the affected kidney was significantly improved from 19.9 mL/min ± 11.2 to 38.1 mL/min ± 11.9 at the 6-month follow-up after PTRA (P < .001).ConclusionsThe overall results of PTRA for pediatric RVH caused by different etiologies are promising. PTRA not only provided a clinical benefit of blood pressure control in 73.3% of the patients but also significantly improved the function of the affected kidney. 相似文献
10.
目的:比较康莱特注射液联合紫杉醇及紫杉醇单纯化疗治疗晚期恶性胸腺瘤的不良反应和疗效。方法:2013年8月至2017年12月,经病理学和免疫组化确诊为恶性胸腺瘤并在我院肿瘤中心进行姑息性化疗的患者68例。康莱特注射液联合化疗为观察组(37例);单纯化疗为对照组(31例)。28天为一周期,共化疗4周期。结果:两组患者均无人发生过敏反应。观察组可有效减轻患者化疗不良反应:恶性、呕吐、四肢麻木、关节肌肉酸痛和白细胞下降(P<0.05),可以有效减轻患者胸闷症状和全身疼痛(P<0.05),在肿瘤控制方面,康莱特联合化疗的疗效较单纯化疗稍好,但均未见有统计学差异(P>0.05)。结论:康莱特注射液联合紫杉醇治疗晚期胸腺瘤,具有减轻患者疼痛、减轻化疗不良反应,从而提高患者化疗依从性的作用,值得临床进一步推广和研究。 相似文献